GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Therapeutic Science Laboratories Inc (OTCPK:RTSL) » Definitions » 3-Year FCF Growth Rate

Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) 3-Year FCF Growth Rate : 59.00% (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Rapid Therapeutic Science Laboratories 3-Year FCF Growth Rate?

Rapid Therapeutic Science Laboratories's Free Cash Flow per Share for the three months ended in Jun. 2023 was $-0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 59.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 22.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Rapid Therapeutic Science Laboratories was 59.00% per year. The lowest was -179.60% per year. And the median was -4.15% per year.


Competitive Comparison of Rapid Therapeutic Science Laboratories's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Rapid Therapeutic Science Laboratories's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Therapeutic Science Laboratories's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Therapeutic Science Laboratories's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Rapid Therapeutic Science Laboratories's 3-Year FCF Growth Rate falls into.



Rapid Therapeutic Science Laboratories 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Rapid Therapeutic Science Laboratories  (OTCPK:RTSL) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Rapid Therapeutic Science Laboratories 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Rapid Therapeutic Science Laboratories's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
5580 Peterson Lane, Suite 120, Dallas, TX, USA, 75201
Rapid Therapeutic Science Laboratories Inc is a biotech company specializing in natural-based relief through aerosol delivery of cannabinoids to the systemic bloodstream through the pulmonary route of administration. The company manufactures its own branded metered dose inhalers (MDI) under the nhaler name using proprietary blends of pure cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG). In addition, the company manufactures other aerosol devices for the delivery of cannabinoids other than MDI such as sublingual sprays.
Executives
Henry Anthony Punzi director 1932 WALNUT PLAZA, CARROLLTON TX 75006
Scott Suggs Justin director 639 SWORD BRIDGE DR., LEWISVILLE TX 75056
Sean Paul Berrier 10 percent owner 7108 DUFFIELD DR., DALLAS TX 75248
Schmidt Donal Ray Jr. director, 10 percent owner, officer: President and CEO 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
Ryan Casey Johnson director, officer: Chief Operating Officer 2307 CASTLE ROCK RD, CARROLTON TX 75007
Texas Mdi, Inc. 10 percent owner 5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
D Hughes Watler director, officer: CFO 2323 S. VOSS ROAD, STE. 510-12, HOUSTON TX 77057
Steve Bond director, officer: CFO 28839 PUJOL ST., #832, TEMECULA CA 92590
Brent Willson director, officer: CEO and President 5271 CAMINITO EXQUISITO, SAN DIEGO CA 92130